Equities

DNAC

KYG8253W1096

Market Closed - Nasdaq Other stock markets 21:00:00 10/05/2024 BST			5-day change	1st Jan Change
2.81 ^USD	+7.66%		+27.73%	-71.44%

2022	Social Capital Suvretta Holdings Corp. III Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	CI
2022	ProKidney Completes SPAC Merger With Social Capital Suvretta Holdings; Shares to Start Nasdaq Trading	MT

Social Capital Suvretta Holdings Corp. III Reports Earnings Results for the Third Quarter and Seven Months Ended September 30, 2021

November 15, 2021 at 10:11 pm

Social Capital Suvretta Holdings Corp. III reported earnings results for the third quarter and seven months ended September 30, 2021. For the third quarter, the company reported net loss was USD 0.25249 million.
For the seven months, net loss was USD 0.257815 million.

Latest news about SOCL CAPI

Social Capital Suvretta Holdings Corp. III Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	12/08/22	CI
ProKidney Completes SPAC Merger With Social Capital Suvretta Holdings; Shares to Start Nasdaq Trading	12/07/22	MT
Social Capital Suvretta Holdings Corp. III(NasdaqCM:DNAC) dropped from NASDAQ Composite Index	12/07/22	CI
ProKidney LLC completed the acquisition of Social Capital Suvretta Holdings Corp. III from SCS Sponsor III LLC, Millennium Management LLC, Adage Capital Management, L.P. and others in a reverse merger transaction.	10/07/22	CI
Social Capital Suvretta Holdings Corp. III Reports Earnings Results for the First Quarter Ended March 31, 2022	16/05/22	CI
Social Capital Suvretta Holdings Corp. III Issues an Unsecured Promissory Note	22/04/22	CI
Social Capital Suvretta Holdings Corp. III announced that it has received $1.5 million in funding from SCS Sponsor III LLC	19/04/22	CI
Social Capital Suvretta Holdings Corp. III Reports Earnings Results for the Ten Months Ended December 31, 2021	24/03/22	CI
ProKidney to Become Publicly Traded via SPAC Merger With Social Capital Suvretta	18/01/22	MT
Palihapitiya-backed SPAC to take biotech ProKidney public in $2.6 bln deal	18/01/22	RE
Palihapitiya-backed SPAC to take ProKidney public in over $2 bln deal	18/01/22	RE
ProKidney LLC executed the non-binding letter of intent to acquire Social Capital Suvretta Holdings Corp. III from SCS Sponsor III LLC, Millennium Management LLC, Adage Capital Management, L.P. and others in a reverse merger transaction.	17/01/22	CI
Social Capital Suvretta Said in Merger Talks With Akili Interactive, ProKidney	10/01/22	MT
Certain Class B Ordinary Shares of Social Capital Suvretta Holdings Corp. III are subject to a Lock-Up Agreement Ending on 27-DEC-2021.	26/12/21	CI
Social Capital Suvretta Holdings Corp. III Reports Earnings Results for the Third Quarter and Seven Months Ended September 30, 2021	15/11/21	CI
Social Capital Suvretta Holdings Corp. III Announces Board Changes	24/09/21	CI
Social Capital Suvretta Holdings Corp. III announced that it has received $6.4 million in funding	01/07/21	CI
Social Capital Suvretta Holdings Corp. III(NasdaqCM:DNAC) added to NASDAQ Composite Index	01/07/21	CI
DNAC : Social Capital Suvretta Holdings Corp. III Shares Climb in Nasdaq Debut	30/06/21	MT

Chart SOCL CAPI

Duration

Period

More charts

Company Profile

Social Capital Suvretta Holdings Corp. III is a blank check company. The Company is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. It has not selected any specific business combination target and has not engaged in any substantive discussions, directly or indirectly, with any business combination target. The Company intend to focus its search for a target business operating in the biotechnology industry and within the organ space subsector of such industry. The Company neither engages in any business operations nor generates any revenues.

Sector

More about the company